

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-26. (Canceled)

27. (Currently Amended) A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering systemically to a subject in need thereof an effective amount of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000750,000 and 900,000 Da.

28. (Canceled)

29. (Currently Amended) The method according to Claim 2827, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

30. (Currently Amended) The method according to Claim 2827, wherein the hyaluronan has a molecular weight of 890,000 Da.

31. (Currently Amended) The method according to Claim 2827, wherein the hyaluronan has a molecular weight of 750,000 Da.

32. (Currently Amended) The method according to Claim 2827, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

33. (Currently Amended) A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering systemically to a subject in need thereof a composition consisting essentially of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000~~750,000~~ and 900,000 Da.

34. (Canceled)

35. (Currently Amended) The method according to Claim 34~~33~~, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

36. (Currently Amended) The method according to Claim 34~~33~~, wherein the hyaluronan has a molecular weight of 890,000 Da.

37. (Currently Amended) The method according to Claim 34~~33~~, wherein the hyaluronan has a molecular weight of 750,000 Da.

38. (Currently Amended) The method according to Claim 34~~33~~, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

39. (Currently Amended) A method for overcoming acquired resistance of cancer cells to a chemotherapeutic agent, said method comprising administering systemically to a subject having said resistant cancer cells an effective amount of a hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a molecular weight between 400,000~~750,000~~ and 900,000 Da.

40. (Canceled)

41. (Currently Amended) The method according to Claim 4039, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

42. (Currently Amended) The method according to Claim 4039, wherein the hyaluronan has a molecular weight of 890,000 Da.

43. (Currently Amended) The method according to Claim 4039, wherein the hyaluronan has a molecular weight of 750,000 Da.

44. (Currently Amended) The method according to Claim 4039, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide

45. (Currently Amended) A pharmaceutical composition consisting essentially of a chemotherapeutic agent and hyaluronan, wherein the hyaluronan has a molecular weight between 400,000~~750,000~~ and 900,000 Da.

46. (Canceled)

47. (Currently Amended) The pharmaceutical composition of Claim 4645, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

48. (Currently Amended) The pharmaceutical composition of Claim 4645, wherein the hyaluronan has a molecular weight of 890,000 Da.

49. (Previously Presented) The pharmaceutical composition of Claim 4645, wherein the hyaluronan has a molecular weight of 750,000 Da.

50. (Currently Amended) The pharmaceutical composition of Claim 4645, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

51. (Previously Presented) A pharmaceutical composition comprising a chemotherapeutic agent and hyaluronan having molecular weight of modal molecular weight of 890,000 Da.

52. (Currently Amended) The pharmaceutical composition of Claim 51, wherein the hyaluronan has molecular weight of 890,000 Da.

53. (Previously Presented) The method according to any one of claims 27, 33, and 39, wherein the hyaluronan has a molecular weight between 750,000 and 890,000 Da.

54. (Previously Presented) The method according to any one of claims 27, 33, and 39, wherein the hyaluronan has a molecular weight between 890,000 and 900,000 Da.

55. (Previously Presented) The pharmaceutical composition according to claim 45, wherein the hyaluronan has a molecular weight between 750,000 and 890,000 Da.

56. (Previously Presented) The pharmaceutical composition according to claim 45, wherein the hyaluronan has a molecular weight between 890,000 and 900,000 Da.